Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT1 | P34896 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | FURIN | P09958 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23106266 | 0.79 | FURIN (0.36) | CTDSP1FURINPOLBKMT2AAKT1 | |
| SCHEMBL23106288 | 0.79 | FURIN (0.38) | SHMT1CTDSP1FURINPOLBKMT2A | |
| SCHEMBL23106135 | 0.79 | FURIN (0.36) | CTDSP1FURINPOLBKMT2AAKT1 | |
| SCHEMBL22184191 | 0.77 | SMN1; SMN2 (0.43) | C3AR1CTDSP1FURINPOLBHPGD | |
| SCHEMBL30831346 | 0.77 | FURIN (0.38) | FURINNPY1R | |
| SCHEMBL7743368 | 0.76 | FURIN (0.36) | SHMT1C3AR1CTDSP1FURINPOLB | |
| SCHEMBL29385639 | 0.75 | C3AR1 (0.45) | SHMT1C3AR1CTDSP1FURINPOLB | |
| SCHEMBL25597931 | 0.74 | C3AR1 (0.41) | SHMT1C3AR1CTDSP1FURINPOLB | |
| SCHEMBL3797302 | 0.74 | FURIN (0.37) | SHMT1C3AR1CTDSP1FURINPOLB | |
| SCHEMBL26695488 | 0.73 | FURIN (0.46) | FURINPOLBKMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630732-B1 | METHOD AND MOLECULES | MEDIMMUNE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20200206359-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206359-A1 | Method And Molecules | PAICS, EPCAM, SQLE | SHMT1 865/4885C3AR1 18/4885CTDSP1 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.